Country of Origin and Tariffs: 5 Myths Hospital Leaders Still Believe

Why Origin And Tariffs Now Matter More

Tariff policies have expanded, enforcement is stricter, and most critical equipment and supplies still come from abroad. Many leaders still treat origin and tariffs as peripheral, assuming group purchasing, vendors, or generic visibility tools address the problem. That assumption no longer holds. Without product-level origin and tariff intelligence, hospitals absorb unplanned cost increases, face shortages, and carry regulatory risk they do not see.

The numbers make the stakes clear. Nearly 70% of medical devices marketed in the U.S. are manufactured exclusively overseas, according to AHA analysis of Census Bureau data, and in 2024 alone the U.S. imported over $75 billion in medical devices and supplies. A survey of 200 healthcare industry experts found that 82% expect tariff-related expenses to raise hospital costs by at least 15% over a six-month period, with 90% of supply chain professionals expecting major procurement disruptions. In this environment, origin and tariff data move from a background detail to a core input for sourcing, contracting, and resilience planning.

Myth 1: "Our GPO Already Handles Tariff Risk"

GPOs negotiate price and terms, but they do not own total landed cost or the way tariffs and sourcing shifts hit your spend between contract cycles. Vendors can pass tariff surcharges through, reclassify products, or switch manufacturing locations while the contract stays in place. The result is unmodeled exposure that shows up as margin pressure, surprise invoices, or forced substitutions.

With item-level tariff and origin visibility, you move from vendor narratives to data. You can quantify tariff impact by item, category, and supplier, identify high-spend SKUs where tariffs drive most of the increase, and bring concrete evidence into negotiations and GPO strategy. Medical supply expenses already collectively accounted for $146.9 billion in 2023, comprising approximately 10.5% of the average hospital's budget, according to AHA analysis. Health systems that model tariff exposure at the SKU level often find tens of millions of dollars at stake across their portfolios.

Myth 2: "Reliable Origin Data At Item Level Is Impossible"

Many hospitals still view accurate country of origin as unattainable at scale, so they rely on partial vendor summaries or ignore origin altogether. Historically, origin fields in item masters have been incomplete, inconsistent, or based on assumptions rather than verified sources. That gap creates blind spots in risk assessment and compliance.

Modern origin datasets use multiple sources for verification, including FDA registrations, manufacturer websites, label image capture, and other regulatory records, and store origin at the packaging level rather than a single value per item. For hospitals, origin becomes a structured attribute for each product and unit of measure, not a vague note. Leaders can segment by sourcing geography, see categories dependent on single regions, and test how specific geopolitical scenarios would affect defined groups of items. The urgency is real: the AHA has confirmed that China alone supplied the majority of N95 respirators used in healthcare in 2023, along with one-third of disposable face masks, two-thirds of non-disposable face masks, and 94% of the plastic gloves used in health care settings. Without origin data at the item level, that exposure is invisible.

Myth 3: "Origin And Tariffs Only Affect Cost, Not Resilience"

Tariffs are often treated as a budget issue and origin as a customs detail. In practice, both are core resiliency signals. Regional instability, pandemics, climate events, and export controls influence production, fill rates, and lead times long before those shifts are fully visible in historical spending. Country of origin ties each product to real-world risk drivers like geography, regulatory regimes, manufacturing quality, and local infrastructure.

When origin and tariff data sit alongside item masters, hospitals can detect single-region dependencies for critical items, design multi-country sourcing strategies, and monitor volatility by region, not only by vendor. The AHA has reported that nearly 60% of drug shortages lasted two or more years in 2024, compared to only one-third of shortages lasting that long in 2019. Origin-informed resilience planning is what separates hospitals that see these disruptions coming from those that absorb them without warning. Origin data also supports ESG and ethical sourcing goals by clarifying where production occurs and where labor or regulatory concerns require closer scrutiny.

Myth 4: "Our Existing Visibility Tools Already Cover This"

Many platforms advertise end-to-end visibility or control towers, but their core focus often remains transactions: open POs, shipments, on-time performance, and spend by vendor or category. These views are useful, yet they rarely show where products are manufactured, which tariff regimes apply, or what alternatives are available if a region becomes high-risk.

Product-centric resiliency views start from a different place. They tie each SKU to verified country of origin at the packaging level, item-level country-specific tariffs updated daily, manufacturing facility data and vendor lineage, substitute availability, and recall or adverse event history tied to the same product identities. Visibility then covers where a shipment is, where and how the product was made, what policy environment governs it, and which substitutes or sourcing paths are ready if conditions change. With 94% of healthcare administrators expecting to delay equipment upgrades to manage financial strain from tariffs, the ability to model real exposure at the item level and act on it before costs hit the P&L is the gap that transaction-based visibility tools do not close.

Myth 5: "Tariff And Origin Decisions Sit Only With Trade Or Legal"

Some executives still place tariffs and origin squarely in trade compliance, legal, or finance. That view underestimates how directly these attributes shape sourcing strategies, contract language, and hospital-level compliance risk. The Department of Justice has brought False Claims Act cases against pharmaceutical distributors for failing to mark imported products with their country of origin, with one settlement resolving $765,000 in allegations tied to customs duty avoidance. The DOJ-HHS False Claims Act Working Group, established in 2025, has expanded priority enforcement areas to include device pricing, kickbacks related to medical devices, and materially defective devices, signaling broader scrutiny of supply chain conduct by providers and their partners.

When origin and tariff datasets are accessible to sourcing and contracting teams, they support adjustments where tariffs and origin concentrate cost and risk, inform contract terms that consider origin diversification, and guide ethical sourcing initiatives. They also help identify where misaligned origin reporting might expose providers or partners to compliance risk tied to trade rules or government purchasing requirements.

How Symmetric's Data Changes Strategy

Symmetric Health Solutions enriches hospital item masters with more than 1,600 attributes, including country of origin, U.S. import tariff rates, GTINs at every unit of measure, UNSPSC, HCPCS, GMDN, and vendor information. Its country of origin and tariff solution helps hospitals identify and close data gaps in high-spend or high-risk categories, model tariff impact on overall spend by item and origin, and monitor fill-rate disruptions segmented by tariff exposure and geography.

Symmetric verifies country of origin through FDA registrations and manufacturer label images, enabling health systems to model potential tariff impacts across tens of millions of dollars in spend and identify equivalent substitutes for critical items. The platform's resiliency control tower connects product, contract, spend, and risk signals in one place, giving teams unified visibility into clinical and supply implications before disruptions reach operations.

By tying origin, tariffs, and substitutes to the same product identities, Symmetric supports multi-country sourcing strategies, surfaces alternatives for high-risk or tariffed items, and provides the evidence needed to push back on unjustified tariff invoice charges.